Clinical trial
An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)
NCT02781480 is registered in ClinicalTrials.gov with MeiraGTx UK II Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)
- Lead sponsor
- MeiraGTx UK II Ltd
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 30, 2016
- Completion date
- December 31, 2018
- Enrollment
- 15 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.